Prime Medicine (NASDAQ:PRME) is a biotechnological company focused on harnessing the power of gene editing to develop treatments for serious diseases. The company's operations revolve around the innovative use of Prime Editing, a next-generation gene editing technology, aiming to correct genetic mutations at their source. Prime Medicine is dedicated to advancing its pipeline of projects targeting a wide range of diseases, with the objective of offering transformative therapeutic options to patients in need. The quest to bring novel therapies from the lab to the clinic underscores their commitment to addressing unmet medical needs.